Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.37 |
| ▸ | TUBB | P07437 | 1/20 | 0.37 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.37 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.37 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.37 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.37 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.37 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.37 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.37 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.37 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.37 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.37 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.37 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664088 | 1.00 | KDM4E (0.42) | KDM4ECREBBPPARP1HRH1ALDH1A1 | |
| SCHEMBL21070262 | 0.84 | PARP1 (0.46) | CREBBPPARP1LMNAMCL1 | |
| SCHEMBL21070644 | 0.83 | ALDH1A1 (0.40) | KDM4ECREBBPHRH1ALDH1A1LMNA | |
| SCHEMBL3913002 | 0.80 | ALDH1A1 (0.52) | KDM4ECREBBPALDH1A1LMNAMAPT | |
| SCHEMBL29612923 | 0.80 | ALDH1A1 (0.52) | KDM4ECREBBPALDH1A1LMNAMAPT | |
| SCHEMBL14671387 | 0.80 | HTR2C (0.38) | PARP1LMNAMCL1 | |
| SCHEMBL20945102 | 0.80 | TNF (0.42) | KDM4EPARP1HRH1ALDH1A1LMNA | |
| Ethoxycarbonyl Group SCHEMBL27492236 | 0.79 | CREBBP (0.42) | KDM4ECREBBPHRH1ALDH1A1LMNA | |
| SCHEMBL21071403 | 0.79 | PARP1 (0.41) | PARP1LMNAMCL1 | |
| SCHEMBL27611518 | 0.78 | PARP1 (0.43) | CREBBPPARP1ALDH1A1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-11318205-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874743-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3731869-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-11-04 | — | — | EP | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874743-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-20230106066-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-20190192668-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
| US-11318205-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | KDM4E 190/4885CREBBP 712/4885PARP1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.